94
Participants
Start Date
January 31, 2009
Primary Completion Date
March 31, 2010
Study Completion Date
March 31, 2010
Placebo for Nasulin
Basal insulin (glargine) administered as a 1x daily injection in the morning and two placebo sprays administered three times daily just prior to meals for 6 weeks.
Nasulin
Basal insulin (glargine) administered as a 1x daily injection in the morning and two (50 IU) or four (100 IU) sprays of Nasulin (intranasal insulin spray 1%) administered three times daily just prior to meals for 6 weeks.
University of Rochester, Rochester
ECU Diabetes Research Center, Greenville
Physician's East PA, Greenville
Mountain Diabetes and Endocrine Center, Asheville
Atlanta Diabetes Associates, Atlanta
University of Miami Diabetes Research Institute, Miami
Metabolic Research Institute, West Palm Beach
Clinical Research of West Florida, Clearwater
Washington University, St Louis
University of Texas; Southwestern Medical Center, Dallas
Texas Diabetes and Endocrinology, Austin
Barbara Davis Center, Aurora
Radiant Research, Chandler
AMCR Institute, Inc, Escondido
Scripps Whittier Diabetes Clinic, La Jolla
Mills-Penninsula Health Services; Dorothy & Frank Diabetes Inst., San Mateo
Diablo Clinical Research, Walnut Creek
East-West Medical Research Institute, Honolulu
Rainier Clinical Research, Renton
Rocky Mountain Clinical Research, Idaho Falls
Maine Research Associates, Auburn
Lead Sponsor
CPEX Pharmaceuticals Inc.
INDUSTRY